Let's crawl before we run. That $30 billion buck market place sure smacks of blue sky at this point. I'll grant you that it is a huge Promise Land. Harry, I'd even love to quaff a few gulps of champagne with you upon approval.
Here's my point of view. It is a lot safer for newbies not to even think about that Promised Land at this point because it will lead to over investing and that's dangerous for the less experienced investors. I'd table any and ALL discussion of unmet medical needs until this Company is in a real Phase III trial with significant success demonstrated by the FDA accepting the results from both a Phase I/II trial.
Some here are unaware that the FDA has at times require 2 separate Phase III trials to prove efficacy. I'm just not certain what the regulatory hurdles will be ahead because this Company is only now getting traction for its first Phase I/II combo trial. I have seen in my own experience, the Medical/Academic Community typically remains skeptical until they see the results duplicated with a separate Phase III trial. It is the old adage... prove to us your success.
All I'm saying is we have a very long road ahead to get to the Promise Land. It is going to require exteme motivation by investors to hang in there with all the road's curves and bumps ahead.
I am not pessimistic at all. We just need to not oversell the benefits and then get blindsided by the costs. And, believe me, there will be major costs ahead.
News 
Market Data 
Discover 
